The abstract is read at the publisher; the summary is JClub's.
US federally sponsored cancer clinical trials (n=11,681; 18.1%) are less likely than industry trials (n=9,569; 81.9%) to be single-agent cancer treatment studies (48.6% vs 77.4%; OR 0.28).
- Why it matters: The US cancer trial landscape is shaped by different sponsor types, but the extent of portfolio differences has not been systematically quantified.
- What they did: The study compared US-based interventional cancer trials registered on ClinicalTrials.gov and initiated between 2008 and 2024, classifying lead sponsors as federal or industry and testing differences with χ² and odds ratios.
- The result: Federal sponsorship was linked to more nontreatment interventional trials, including prevention (4.7% vs 1.1%; OR 4.43) and supportive care (2.5% vs 0.9%; OR 2.92), plus higher use of multimodality regimens, deescalation designs, rare cancer focus (17.5% vs 12.1%; OR 1.54), and pediatric trials (16.1% vs 5.3%; OR 3.43).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.